Acrivon Therapeutics, Inc. (ACRV)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Acrivon Therapeutics, Inc. (ACRV)
Company Performance

Current Price

as of Oct 16, 2024

$7.75

P/E Ratio

N/A

Market Cap

$240.03M

Description

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Metrics

Overview

  • HQWatertown, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerACRV
  • Price$7.75+1.97%

Trading Information

  • Market Cap$240.03M
  • Float70.10%
  • Average Daily Volume (1m)105,558
  • Average Daily Volume (3m)92,246
  • EPS-$2.77

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$18.80M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$21.24M
  • EV$33.25M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B1.11
Documents